Two retrospective analyses of programmed cell death 1/programmed cell death ligand 1-directed immune checkpoint inhibitors in patients with MET exon 14 skipping NSCLC indicate poor response rates (ORR: 16–17%), although data specifically for Japanese patients were unavailable (22,23). Here, MET is linked to non-small cell lung carcinoma.